



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

RECEIVED  
SEP 29 2003  
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**11245/46605**

Application Number  
**09/996,954**

Filing Date  
**November 30, 2001**

Examiner  
**To be assigned**

Art Unit  
**1642**

Invention Title  
**TREATMENT OF REFRACTORY HUMAN  
TUMORS WITH EPIDERMAL GROWTH FACTOR  
RECEPTOR ANTAGONISTS**

Inventor(s)  
**Harlan W. WAKSAL**

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-  
1450 on

Date: September 22, 2003

By: Kathryn M. Lumb  
Kathryn M. Lumb, Reg. No. 46,885

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: September 22, 2003

By: Kathryn M. Lumb  
Kathryn M. Lumb  
(Reg. No. 46,885)  
Kenyon & Kenyon  
One Broadway  
New York, New York 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
**CUSTOMER NO. 26646**



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT  
BY APPLICANT PTO-1449**

ATTY. DOCKET NO.  
**11245/46605**

SERIAL NO.  
**09/996,954**

APPLICANT  
**WAKSAL et al.**

FILING DATE  
**November 30, 2001**

GROUP  
**1642**

RECEIVED  
SEP 28 2003  
TECH CENTER 1600/2900

**U. S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	6,605,448	August 12, 2003	Piecznik			
	5,866,363	February 2, 1999	Piecznik			

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER'S INITIALS		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	DATE CONSIDERED
EXAMINER Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	